KR102443258B1 - 항 cd40 항체에 의한 병용 치료제 - Google Patents

항 cd40 항체에 의한 병용 치료제 Download PDF

Info

Publication number
KR102443258B1
KR102443258B1 KR1020177005821A KR20177005821A KR102443258B1 KR 102443258 B1 KR102443258 B1 KR 102443258B1 KR 1020177005821 A KR1020177005821 A KR 1020177005821A KR 20177005821 A KR20177005821 A KR 20177005821A KR 102443258 B1 KR102443258 B1 KR 102443258B1
Authority
KR
South Korea
Prior art keywords
antibody
tumor
antigen
seq
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177005821A
Other languages
English (en)
Korean (ko)
Other versions
KR20170041790A (ko
Inventor
페테르 엘마르크
페르 놀렌
니나 베이톤메키
Original Assignee
엘리게이터 바이오사이언스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102443258(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by 엘리게이터 바이오사이언스 에이비 filed Critical 엘리게이터 바이오사이언스 에이비
Publication of KR20170041790A publication Critical patent/KR20170041790A/ko
Application granted granted Critical
Publication of KR102443258B1 publication Critical patent/KR102443258B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177005821A 2014-08-12 2015-08-12 항 cd40 항체에 의한 병용 치료제 Active KR102443258B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB1414270.7 2014-08-12
GB201422614 2014-12-18
GB1422614.6 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
GB1507541.9 2015-05-01
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (2)

Publication Number Publication Date
KR20170041790A KR20170041790A (ko) 2017-04-17
KR102443258B1 true KR102443258B1 (ko) 2022-09-14

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005821A Active KR102443258B1 (ko) 2014-08-12 2015-08-12 항 cd40 항체에 의한 병용 치료제

Country Status (25)

Country Link
US (3) US11149090B2 (cg-RX-API-DMAC7.html)
EP (3) EP3552665A3 (cg-RX-API-DMAC7.html)
JP (1) JP6654187B2 (cg-RX-API-DMAC7.html)
KR (1) KR102443258B1 (cg-RX-API-DMAC7.html)
CN (3) CN119280407A (cg-RX-API-DMAC7.html)
AU (1) AU2015303164B2 (cg-RX-API-DMAC7.html)
CA (1) CA2957146A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000335A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017001317A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170096A (cg-RX-API-DMAC7.html)
DK (1) DK3180087T3 (cg-RX-API-DMAC7.html)
EA (1) EA201790339A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17008984A (cg-RX-API-DMAC7.html)
ES (1) ES2725463T3 (cg-RX-API-DMAC7.html)
IL (1) IL250512B (cg-RX-API-DMAC7.html)
MA (1) MA47472A (cg-RX-API-DMAC7.html)
MX (1) MX382549B (cg-RX-API-DMAC7.html)
NI (1) NI201700015A (cg-RX-API-DMAC7.html)
PE (1) PE20170680A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500229A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701070WA (cg-RX-API-DMAC7.html)
SV (1) SV2017005380A (cg-RX-API-DMAC7.html)
UA (1) UA119783C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016023960A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701126B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
FI3447075T3 (fi) 2015-05-15 2023-11-07 Massachusetts Gen Hospital Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
AU2017263833B2 (en) * 2016-05-13 2023-08-03 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
MA45672A (fr) * 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
WO2018078620A1 (en) 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities
AU2017353852A1 (en) * 2016-11-02 2019-05-23 Apexigen, Inc. Anti-CD40 antibodies in combination and methods of use
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
WO2019043170A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh POLY THERAPY BASED ON HSP70
MX2020009510A (es) * 2018-03-13 2021-08-05 Hibercell Inc Inmunoterapia combinada de beta glucano y agonista cd40.
WO2019241306A2 (en) * 2018-06-12 2019-12-19 Neon Therapeutics, Inc. Combination therapy with neoantigen vaccine
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
KR102715542B1 (ko) * 2018-08-20 2024-10-08 화이자 인코포레이티드 항-gdf15 항체, 조성물 및 사용 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
KR20210099027A (ko) * 2018-11-30 2021-08-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
MX2021014572A (es) * 2019-05-28 2022-03-17 Janssen Biotech Inc Metodo para proporcionar la administracion segura de un anticuerpo anti-cd40.
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4083210A1 (en) * 2019-12-27 2022-11-02 Interoligo Corporation Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023064878A1 (en) * 2021-10-15 2023-04-20 The Rockefeller University Combination of anti-cd40 antibody and il-15 for treating cancer
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
AU2022463987A1 (en) 2022-06-23 2025-01-09 Alligator Bioscience Ab Combination therapies
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010024676A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002048351A2 (en) 2000-12-12 2002-06-20 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
MXPA06012430A (es) 2004-04-27 2007-04-19 Novartis Vaccines & Diagnostic Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AU2010295687B2 (en) * 2009-09-16 2014-11-06 E. I. Du Pont De Nemours And Company Chiller apparatus containing trans-1,1,1,4,4,4-hexafluoro-2-butene and methods of producing cooling therein
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
PE20160753A1 (es) 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3283107T3 (da) 2015-04-17 2020-08-31 Bristol Myers Squibb Co Sammensætninger omfattende en kombination af ipilimumab og nivolumab
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2016285913B2 (en) 2015-06-29 2022-06-16 Bristol-Myers Squibb Company Antibodies to CD40

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010024676A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. Vonderheide et al., Agonistic CD40 Antibodies and Cancer Therapy, Clinical Cancer Research, 2013, vol. 19, pp.1035-1043

Also Published As

Publication number Publication date
US20240132609A1 (en) 2024-04-25
CR20170096A (es) 2017-06-15
ZA201701126B (en) 2025-08-27
EP4653463A2 (en) 2025-11-26
MX382549B (es) 2025-03-13
CL2017000335A1 (es) 2017-08-11
IL250512B (en) 2021-08-31
WO2016023960A1 (en) 2016-02-18
BR112017002729A2 (pt) 2018-02-27
MA47472A (fr) 2019-12-18
SV2017005380A (es) 2018-09-14
JP2017524715A (ja) 2017-08-31
DK3180087T3 (da) 2019-05-13
EP3552665A2 (en) 2019-10-16
NZ729270A (en) 2024-03-22
EP3552665A3 (en) 2019-12-18
JP6654187B2 (ja) 2020-02-26
CA2957146A1 (en) 2016-02-18
PH12017500229A1 (en) 2017-07-10
CN114099671A (zh) 2022-03-01
EP3180087B1 (en) 2019-03-13
MX2017001864A (es) 2017-08-02
NI201700015A (es) 2017-05-12
UA119783C2 (uk) 2019-08-12
IL250512A0 (en) 2017-03-30
EP3180087A1 (en) 2017-06-21
SG11201701070WA (en) 2017-03-30
CN106573981A (zh) 2017-04-19
US20210403589A1 (en) 2021-12-30
US20170226217A1 (en) 2017-08-10
ES2725463T3 (es) 2019-09-24
US20240228643A9 (en) 2024-07-11
AU2015303164A1 (en) 2017-03-09
AU2015303164B2 (en) 2020-10-29
ECSP17008984A (es) 2017-05-31
US11149090B2 (en) 2021-10-19
CO2017001317A2 (es) 2017-08-10
EA201790339A1 (ru) 2017-06-30
PE20170680A1 (es) 2017-06-14
CN119280407A (zh) 2025-01-10
KR20170041790A (ko) 2017-04-17

Similar Documents

Publication Publication Date Title
KR102443258B1 (ko) 항 cd40 항체에 의한 병용 치료제
US11136392B2 (en) PD-1 immune modulating agents
RU2744959C2 (ru) Новые анти-pd-l1 антитела
JP7360441B2 (ja) メソテリン及びｃｄ１３７結合分子
JP2022020862A (ja) Ｃｄ３９と結合する抗体及びその使用
JP2021522801A (ja) ヒトネクチン４に特異的な抗体
JP2023545057A (ja) 抗デクチン－１抗体及びその使用方法
KR20210030957A (ko) 항-메소텔린 항체
KR20190022632A (ko) Lag-3 결합 구성원
US20240409643A1 (en) Anti-nmdar2b antibodies, antibody-drug conjugates, and chimeric antigen receptors, and compositions and methods of use
RS65211B1 (sr) Bispecifična antitela protiv ceacam5 i cd47
JP2024522234A (ja) 新規な併用療法及びその使用
US20250230256A1 (en) Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
RU2815066C2 (ru) Молекулы, связывающие мезотелин и cd137
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4